

## **Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Therapeutics-announce-major-milestone/**

December 16, 2021 6:00 am Published by [Nova Mentis Life Science Corp](https://novamentis.ca/news/author/adfsdhrrfvh/)



**December 16, 2021 – Nova Mentis Life Science Corp** (<https://www.novamentis.ca/>), (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a company focused on developing advanced drug delivery systems for use with psychedelic compounds, announce the successful milestone of merging NOVA

The initial permeation studies using human skin are underway at Mycrodose Therapeutics laboratories in San Diego, CA to prove that NOVA's drug compound for Autism Spectrum Disorder (“ASD”), may not require a high dose of a psychedelic compound, or a large macrodose amount of drug, for a patient to benefit therapeutically.

“This cooperative transdermal delivery technology expands the possibilities of treating chronic developmental disorders such as Fragile X Syndrome without a clinical environment, which goes a long way to save time for our overworked medical community and lower medical costs for families with disabled children.”

NOVA successfully completed four preclinical studies confirming the therapeutic efficacy of the company's proprietary psilocybin-based drug and established a clear pathway to drug approval.

“We are thrilled with our ongoing permeability research and look forward to continuing the efforts to co-create a product with NOVA that safely and accurately delivers an improved approach to delivering pharmaceutical compounds to patients who are not suited for or unwilling to accept the risks associated with a macrodose.”

Mycrodose's state-of-the-art laboratory in Southern California offers a wide range of capabilities, integrating an advanced analytical chemistry department with parameters critical for the successful and optimum delivery of an API. In addition, stability-indicating assays are being implemented to assess and assure the quality of the drug.

In October 2021, the two companies entered into a Letter of Intent (“LOI”) to form a Joint Venture (“NewCo”) that will accelerate the research and development of the inherited cause of ASD. NewCo aims to be in clinical FDA trials in Q1 2022 with this novel technology.

### **About Mycrodose Therapeutics**

[Mycrodose Therapeutics](https://mycrodogethera.com/) (<https://mycrodogethera.com/>) is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of a novel approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

For more information about Mycrodose Therapeutics, please contact:

[Patrick Eckstrom](https://www.linkedin.com/in/patrickeckstrom/) (<https://www.linkedin.com/in/patrickeckstrom/>),

Chief Operating Officer

Mycrodose Therapeutics

Email: [Patrick@MycrodoseThera.com](mailto:Patrick@MycrodoseThera.com) (<mailto:Patrick@MycrodoseThera.com>)

Phone: 1-619-494-1367

Website: [www.MycrodoseThera.com](http://www.mycrodogethera.com) (<http://www.mycrodogethera.com>)

### **About Nova Mentis Life Science Corp.**

[Nova Mentis Life Science Corp.](https://www.novamentis.ca/) (<https://www.novamentis.ca/>) is a Canadian-based biotechnology company and global leader in developing diagnostics and drug delivery systems. The biotech company to receive psilocybin FXS orphan drug designation in the U.S. and European Union, which will greatly assist the company on the pathway to clinical trials.

For further information on the Company, please visit [novamentis.ca](mailto:novamentis.ca) (<mailto:novamentis.ca>), or email [info@novamentis.ca](mailto:info@novamentis.ca) (<mailto:info@novamentis.ca>).

On Behalf of the Board

***Will Rascan, President & CEO*** (<https://www.linkedin.com/in/willrascan/?originalSubdomain=ca>)

Nova Mentis Life Science Corp.

Phone: 778-819-0244

Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the accuracy or completeness of this information.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those stated in such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the word "will" or similar expressions.

[\\_\(/#facebook\)](#), [\\_\(/#twitter\)](#), [\\_\(/#linkedin\)](#), [\\_\(/#email\)](#),  
[\\_\(/https://www.addtoany.com/share?url=https%3A%2F%2Fnovamentis.ca%2Fnews%2Fmilestone%2F&title=Nova%20Mentis%20and%20Mycrodose%20Therapeutics%20Announce%20Major%20Milestone\)](https://www.addtoany.com/share?url=https%3A%2F%2Fnovamentis.ca%2Fnews%2Fmilestone%2F&title=Nova%20Mentis%20and%20Mycrodose%20Therapeutics%20Announce%20Major%20Milestone)

[Back to News](#)

### Corporate Head Office

Phone: 778-819-0244 (tel:7788190244)

Toll Free: 1-833-542-5323

Email: [info@novamentislsc.com](mailto:info@novamentislsc.com)

Transfer Agent: Computershare

Tel: 604-661-9400 (tel:6046619400)

Auditor: Smythe LLP

Tel: 604-687-1231 (tel:6046871231)

Legal Counsel: Richards Buell Sutton LLP

Tel: 604-682-3664 (tel:604-682-3664)

<https://www.rbs.ca/> (<https://www.rbs.ca/>)

### Contact Us

Address:

700-838 West Hasting Street Vancouver, B.C. Canada

V6C 0A6

Phone number:

778-819-0244

Toll Free:

1-833-542-5323

E-mail:

[info@novamentis.ca](mailto:info@novamentis.ca)


### Follow Us

  
<https://www.youtube.com/channel/UCXD1Nhg8ihg2K6obL3->  
<https://www.facebook.com/novamentislsc/>  
<https://twitter.com/novamentislsc/>

### Latest from Twitter

Tweets by @NovaMentisLSC

Nova Mentis Life Science Corp. Retweeted

 Microdose Psychedelic Insights  
@MicrodoseHQ

[\\$NOVA](#) [\\$NMLSF](#) @NovaMentisLSC and Mycrodose Therapeutics announce the successful milestone of merging NOVA's [#psilocybin](#)-based drug development program with Mycrodose's transdermal technology. [#psychedelics](#) [#medicine](#) [#CSE](#) [#traders](#) [#transdermal](#) [#technologyprn.to/3H4Jecb](#)



Dec 16, 2021

[Embed](#)

[View on Twitter](#)

### Subscribe

Subscribe to our mailing list

**WEBSITE  
POWERED BY  
100%  
RENEWABLE  
ENERGY** (<https://whc.ca/green-powered/?aff=3153&gbid=3en>)

